Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX1 | P51575 | 11/20 | 0.64 |
| ▸ | KCNMA1 | Q12791 | 3/20 | 0.64 |
| ▸ | TMPRSS4 | Q9NRS4 | 7/20 | 0.62 |
| ▸ | P2RX4 | Q99571 | 5/20 | 0.62 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.62 |
| ▸ | CA1 | P00915 | 1/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.60 |
| ▸ | CDK1 | P06493 | 1/20 | 0.57 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.53 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.53 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | IKBKB | O14920 | 1/20 | 0.53 |
| ▸ | CHUK | O15111 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | FLT3 | P36888 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MYLK | Q15746 | 1/20 | 0.53 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3814303 | 0.85 | P2RX1 (0.53) | P2RX1KCNMA1TMPRSS4P2RX4P2RX7 | |
| SCHEMBL11324189 | 0.84 | P2RX1 (0.68) | P2RX1KCNMA1TMPRSS4P2RX4P2RX7 | |
| SCHEMBL3787454 | 0.84 | ALDH1A1 (0.50) | P2RX1KCNMA1TMPRSS4CA1CA2 | |
| SCHEMBL5506621 | 0.82 | P2RX1 (0.66) | P2RX1KCNMA1TMPRSS4P2RX4P2RX7 | |
| SCHEMBL7987535 | 0.82 | ALDH1A1 (0.67) | CA1CA2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL11768955 | 0.81 | P2RX1 (0.44) | P2RX1KCNMA1TMPRSS4P2RX4P2RX7 | |
| SCHEMBL3277584 | 0.81 | ALDH1A1 (0.70) | P2RX1KCNMA1TMPRSS4P2RX4P2RX7 | |
| SCHEMBL17481527 | 0.81 | GAA (0.58) | P2RX1KCNMA1TMPRSS4P2RX4P2RX7 | |
| SCHEMBL19141069 | 0.81 | P2RX1 (0.64) | P2RX1KCNMA1TMPRSS4P2RX4P2RX7 | |
| SCHEMBL824657 | 0.81 | JAK2 (0.49) | P2RX1KCNMA1TMPRSS4MEN1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170152260-A1 | STAT3 INHIBITOR | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-06-01 | — | — | US | disclosed |
| EP-1891064-B1 | N-AMIDE DERIVATIVES OF 8-AZABICYCLO[3.2.1]OCT-3-YL AS CCR1 ANTAGONISTS | ALMIRALL SA (ES) | 2009-09-02 | — | — | EP | disclosed |
| EP-1891064-B1 | N-AMIDE DERIVATIVES OF 8-AZABICYCLO[3.2.1]OCT-3-YL AS CCR1 ANTAGONISTS | ALMIRALL SA (ES) | 2009-09-02 | — | — | EP | disclosed |
| US-20090130090-A1 | N-amide Derivatives of 8-Azabicyclo[3.2.1]OCT-3-YL AS CCR1 Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-05-21 | — | — | US | disclosed |
| US-20090130090-A1 | N-amide Derivatives of 8-Azabicyclo[3.2.1]OCT-3-YL AS CCR1 Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-05-21 | — | — | US | disclosed |
| US-20090130090-A1 | N-amide Derivatives of 8-Azabicyclo[3.2.1]OCT-3-YL AS CCR1 Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-05-21 | — | — | US | disclosed |
| CN-101228158-A | N-amide derivatives of 8-azabicyclo[3.2.1]oct-3-yl as ccr1 antagonists | ALMIRALL LAB (ES) | 2008-07-23 | — | — | CN | disclosed |
| EP-1891064-A1 | N-AMIDE DERIVATIVES OF 8-AZABICYCLO[3.2.1]OCT-3-YL AS CCR1 ANTAGONISTS | Laboratorios Almirall, S.A. (ES) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006133802-A1 | N-AMIDE DERIVATIVES OF 8-AZABICYCLO[3.2.1]OCT-3-YL AS CCR1 ANTAGONISTS | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152260-A1 | STAT3 INHIBITOR | STAT3, STAT1, STAT4 | P2RX1 4177/4885KCNMA1 4724/4885TMPRSS4 785/4885 |
| US-20090130090-A1 | N-amide Derivatives of 8-Azabicyclo[3.2.1]OCT-3-YL AS CCR1 Antagonists | CCR1, CCR3, CCR8 | P2RX1 1025/4885KCNMA1 2829/4885TMPRSS4 4059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.